ASPREE试验长期随访:老年人阿司匹林与癌症发病及死亡
低剂量阿司匹林与总体癌症发病率无关(HR=0.98),但癌症相关死亡风险升高(HR=1.15);停药后观察期未见遗留效应。
要点
- 低剂量阿司匹林未降低老年人总体癌症发病率。
- 阿司匹林组癌症相关死亡风险升高,HR=1.15。
- 随机期后观察阶段未见癌症发病或死亡的遗留效应。
核心结论
- 在老年人中随访中位8.6年,低剂量阿司匹林与总体癌症发病率无关,但癌症相关死亡风险显著升高。
- 随机期观察到的癌症死亡风险升高未持续至随机后观察期,提示无遗留效应。
研究设计与样本
- 社区来源双国(澳大利亚和美国)队列研究,源自2010至2017年ASPREE随机临床试验,观察延展ASPREE-XT随访至2024年。
- 共19 114名无显性心血管病、痴呆或限制独立生活身体残疾的社区老年人,平均年龄75.1岁,56.4%女性。
- 干预为每日100 mg阿司匹林或安慰剂,从随机化至研究药物停止。
主要发现
- 10年随访(中位8.6年)期间共发生3448例新发癌症和1173例癌症相关死亡。
- 低剂量阿司匹林与长期总体癌症发病率无关(HR=0.98;95%CI 0.92-1.05),按诊断分期或癌症类型(包括结直肠癌HR=1.01;95%CI 0.84-1.21)均无关。
- 低剂量阿司匹林与癌症相关死亡风险升高相关(HR=1.15;95%CI 1.03-1.29)。
- 随机期无癌症并进入ASPREE-XT的14 907名参与者中,随机期原阿司匹林分配与随机后癌症发病率(HR=0.91;95%CI 0.82-1.01)或癌症相关死亡(HR=1.02;95%CI 0.83-1.25)无关。
临床怎么用
- 对无心血管疾病的老年人,不应以降低癌症发病为目的处方低剂量阿司匹林。
- 需权衡阿司匹林相关癌症死亡风险升高信号,个体化评估用药指征。
局限性
- 研究为ASPREE试验及其观察延展的队列分析,非独立前瞻随机对照验证。
- 原文未报告按癌症类型或分期的死亡率亚组结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Prior studies, largely among middle-aged adults, reported aspirin reduces cancer risk after 10 years, particularly for colorectal cancer (CRC). In contrast, the Aspirin in Reducing Events in the Elderly (ASPREE) randomized clinical trial (RCT) reported that low-dose aspirin (LDA) treatment for a median of 4.7 years had no effect on overall cancer incidence but increased risk of incident late-stage cancer and cancer-related mortality. OBJECTIVE: To assess whether LDA is associated with cancer incidence and mortality in 10 years of follow-up in older adults (aged ≥70 years) and to assess the association with cancer after prior LDA exposure (legacy effects). DESIGN, SETTING, AND PARTICIPANTS: This community-based binational (Australian and US) cohort study included community-dwelling older adults (aged ≥70 years for Australian participants and ≥65 years for US minority group participants) free from overt cardiovascular disease, dementia, or independence-limiting physical disability. The cohort was derived from the ASPREE randomized clinical trial conducted from 2010 to 2017, with the observational extension study (ASPREE-XT) following up participants from 2018 to 2024. This study reports data from 2010 through 2022 (long-term outcomes) as well as reports analyses confined to the observation phase only (legacy analyses). Data were analyzed from May to November 2025. INTERVENTION: Daily 100-mg aspirin or placebo from randomization until cessation of study drug. MAIN OUTCOMES AND MEASURES: Outcomes were physician-adjudicated incident cancer, type, stage at diagnosis, and cancer mortality. RESULTS: In 19 114 community-dwelling older adults (mean [SD] age, 75.1 [4.5] years; 56.4% female), a total of 3448 incident cancers and 1173 cancer-related deaths occurred over 10 years of follow-up (median, 8.6 [IQR, 7.4-10.0] years) during ASPREE and ASPREE-XT. LDA was not associated with overall cancer incidence over the long term (hazard ratio [HR] = 0.98; 95% CI, 0.92-1.05), by stage at diagnosis or cancer type, including colorectal cancer (HR = 1.01; 95% CI, 0.84-1.21). However, LDA was associated with increased cancer-related mortality (HR = 1.15; 95% CI, 1.03-1.29). Among 14 907 participants without cancer during the RCT and consented into ASPREE-XT (median age, 78.6 years [IQR, 76.2-82.1]; 57.5% female), 1451 incident cancers and 376 cancer deaths occurred in the post-RCT period, during which original aspirin assignment during the RCT was not associated with differences in cancer incidence (HR = 0.91; 95% CI, 0.82-1.01) or cancer-related mortality (HR = 1.02; 95% CI, 0.83-1.25) compared with original placebo assignment. CONCLUSIONS AND RELEVANCE: In this study, over a median of 8.6 years, LDA was not associated with incident cancer among older adults, but cancer mortality risk was significantly elevated. However, the elevated cancer mortality risk seen with aspirin for participants in the RCT period did not persist into the post-RCT observation period, suggesting no legacy effect.
引用
- Orchard SG, Polekhina G, Zalcberg J, et al. Cancer Incidence and Mortality With Aspirin in Older Adults: Follow-Up of the ASPREE Trial. JAMA Oncol. 2026. PMID: 41609798. doi:10.1001/jamaoncol.2025.6196
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。